Last checked at 17 Jan 2020 16:34
17 January 2020
IXICO plc
("IXICO" or the "Company")
Results of AGM
IXICO plc (AIM: IXI), the AI data analytics company delivering insights in neuroscience, can announce that resolutions one to five were put forward to its Annual General Meeting held earlier today and were duly passed whilst resolution six was not duly passed. The votes cast at the meeting were as follows:
Resolution | Description | Total Votes For | % Votes | Total Votes Against | % Votes | Withheld | Votes cast as a % of ISC |
1 | Reports and Accounts | 21,954,961 | 100.00% | 200 | 0.00% | 800 | 46.62 |
2 | Re-election of Directors | ||||||
2a | Re-election of Giulio Cerroni | 21,955,461 | 100.00% | 500 | 0.00% | 0 | 46.62 |
2b | Re-election of Grant Nash | 21,955,461 | 100.00% | 500 | 0.00% | 0 | 46.62 |
3 | Re-appointment of Auditors | 21,949,261 | 99.99% | 1,700 | 0.01% | 5,000 | 46.61 |
4 | Allotment of Securities | 21,953,961 | 99.99% | 1,700 | 0.01% | 300 | 46.62 |
5 | Disapply Pre-Emption Provisions | 21,953,761 | 99.99% | 1,900 | 0.01% | 300 | 46.62 |
6 | Amendment of Rule 3 of the Long-Term Incentive Plan | 10,641,004 | 48.48% | 11,309,157 | 51.52% | 5,800 | 46.61 |
Charles Spicer, Chairman of the Board of IXICO, commented:
"The board notes the results of the resolution to approve the amendment to the IXICO LTIP and, over the coming months, will engage with those major shareholders who did not support this resolution to understand their concerns."
For further information please contact:
| |||||||||||||||||
|
About IXICO
IXICO's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience and rare disease.
Our goal is to be a leading proponent in the use of Artificial Intelligence (AI) in clinical development, to improve biopharma R&D productivity through the adoption of breakthrough data analytics in precision healthcare. Through the deployment of novel AI algorithms, we analyse and interpret brain scans and digital biosensor data to enable better trial design, patient selection and ultimately clinical outcomes across all phases of clinical evaluation. Our data analytics services are deployed on some of the most important clinical trials in neuroscience, providing valuable insights to disease progression and patient safety, enabling our clients to make better informed decisions earlier in the clinical development pathway.
More information is available on www.IXICO.com